Meriem Messaoudene PhD, is a post-doc in Dr. Bertrand Routy’s laboratory “oncomicrobiome” at the CRCHUM (Montréal, Canada). She specialized in the impact of the microbiome on immunotherapy response. After studying basic immunology at the UPMC and Institut Pasteur (Paris), she went on to complete a PhD at the Université Paris-Saclay on the role of NK cells in human metastatic melanoma. She then continued during two years with a postdoctoral fellowship in Pr. Laurence Zitvogel’s lab (Institut Gustave Roussy. She is now focusing on the impact of Castalagin prebiotic on the gut microbiota and immune response to anti-PD-1 therapy.
Dr. Bertrand Routy MD, PhD is a young clinician-scientist and associate professor in the department of hemato-oncology at the CHUM (University of Montreal) with clinical expertise in lung cancer. Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Pr. Laurence Zitvogel, Dr. Routy quickly established himself as director of the CRCHUM oncomicrobiome research unit where he began work to develop novel microbiome-based therapeutics in oncology. His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibiotic-related gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Moreover, he demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiota-centered trials in oncology. Dr. Routy is internationally recognized as a leader in the microbiome field with more than 12,000 citations including publications in Science, Nature Medicine and Annals of oncology and h-index of 35. Moreover, his unending commitment to improving immunotherapy responses in cancer patients has led to several awards from prestigious societies including the 2021 Gairdner Foundation award, young investigator of Quebec award and the 2022 Terry Fox Clinician Scientist Award.
Iris Kalka is a Ph.D. candidate in Pr. Eran Segal's laboratory. She studied computer science focused of bioinformatics before specializing in systems biology in her M.Sc. at the Weizmann Institute of Science (Israel). After a fellowship in University of Chicago's Data Science for Social Good program she returned to a Ph.D. in Pr. Eran Segal's laboratory. As a Seerave Fellow, Iris is involved in profiling immune responses of cancer patients by leveraging high throughput antibody repertoire profiling methodologies.
- Machine Learning
- Systems Biology
Carolina Alves Costa Silva
Carolina Alves Costa Silva is a Ph.D. candidate in Pr. Laurence Zitvogel’s laboratory “Immunologie des tumeurs et immunothérapie contre le cancer”. She did Medical School at Federal University of Bahia, Medical Residency in Internal Medicine and Medical Oncology at Sao Paulo University (Brazil). After working as a Medical Oncologist at Oncoclínicas (Brazil), she first came to Gustave Roussy as a DUERTECC fellow at Genitourinary Department (Dr. Laurence Albiges). She is currently investigating the antitumor effects of key metabolites found in Pr. Zitvogel and Pr. Kroemer’s ONCOBIOME cohorts, notably ketoglutarate. She also works in the kidney cancer clinics for the KETOREIN trial.
As the CAO, he uses his expertise in microbiome science and machine learning methodologies to guide the company’s strategy for translating copious amounts of cell-free microbiome data into patient diagnoses. At only age 28, Micronoma is Greg’s third corporation and was strongly inspired by the unexpected stage IV diagnosis and tragic sudden loss of his grandmother to pancreatic cancer while attending college.
Sarah Schenck is a writer, director, and producer. She uses storytelling to advance public health goals for diverse audiences. Sarah creates shorts for nonprofits and teaches meditation at St. Francis Friends of the Poor. While serving as the NYC Comptroller’s Senior Education Policy Advisor she taught herself filmmaking. Sarah directed, produced, and was the correspondent for Saving Carla, a film on childhood obesity that aired on PBS. She co-founded ParentEarth, dedicated to healthy food for all families. Her films have won awards at festivals worldwide. Sarah’s latest film, The Invisible Extinction, showcases the critical role microbes play in human health.
Head of Microfluidics
Hervé is the Head of Microfluidics of Xsensio. He leads the development of innovative solutions for the collection and transport of novel biofluids for the Lab-on-SkinTM sensing platform. After a MSc in Physics at ENS Ulm, he earned a PhD in fluid-structure interactions from Sorbonne Université. Before joining Xsensio, Hervé obtained several grants to join international research groups in Santiago de Chile and EPFL, where he unraveled new fundamental knowledge in 2D materials and microfluidics. Xsensio SA is a swiss start-up that develops innovative wearable systems that continuously monitor our physiological state to detect risks in real-time.
Chief Scientific Officer
Eddie Adams is the Chief Scientific Officer of Micronoma, Inc. At Micronoma he leads the development of the Oncobiota™ cell-free microbial DNA liquid biopsy assays for cancer detection. He received his PhD in Biological Chemistry in Peter Seeberger’s laboratory from the Massachusetts Institute of Technology and carried out postdoctoral work in innate immunity with Prof. Nir Hacohen at Harvard Medical School. His industrial research career has encompassed development and successful commercialization of products in nanotechnology, epigenetics, microbiome sample preparation solutions, and disease diagnostics for sepsis and cancer. Eddie is an inventor on 17 issued patents and numerous patent applications.
Assay Development Lead & Co-Founder
Hanie is a biotech innovator and the co-founder of Arma Biosciences with experience in development of biomedical devices. Focused on combination of surface chemistry, electrochemistry and molecular biology during the past seven years, Hanie has developed multiple patented sensing technologies for food safety, and disease monitoring.
Director of RnD & Co-Founder
Surath is an engineer and academic who co-founded Arma Biosciences, developing a platform biosensing technology rooted from his PhD work published in Nature Chemistry. His passion for science is seen in his publications, patents, and in having organised Canada’s foremost science outreach festival, Science Rendezvous.
He is the CEO and Co-founder of AIcrowd, a platform for organising machine learning challenges on a variety of problems in OpenScience using OpenData. The vision is to enable Scientists from multiple domains to crowdsource machine learning expertise; and in the process also facilitate the grooming of machine learning expertise in a coopetitive environment. He was previously working as a PhD student at École polytechnique fédérale de Lausanne (EPFL), Switzerland working on a diversity of problems in Applied Machine Learning from detection of Plant Diseases from images of Plant leaves to teaching musculoskeletal models how to walk using reinforcement learning. Currently Mohanty is involved in the MyFoodRepo project.
University of Strathclyde
Damion Corrigan is a Lecturer and Chancellor's Fellow in the Department of Biomedical Engineering at the University of Strathclyde. His area of expertise is the electrochemical detection of disease markers, particularly for infectious conditions. Based on core expertise in electrochemical sensing, analytical chemistry and device fabrication his research aims to develop improved diagnostic tests for clinically important conditions such as, drug resistant bacterial infections, COVID-19, sepsis, cancer and epilepsy.
Adrian is a co-founder of Xsensio, and its CSO. He is also a full Professor at EPFL, where he leads the Nanolab. He received his Ph.D. degree from the National Polytechnic Institute of Grenoble in France, and has held staff and/or visiting positions at LETI-CEA and LPCS-ENSER in Grenoble, at Stanford University, and at Tokyo Tech. He has published more than 350 articles in international journals and conference.
Director of Biosensing
Ron is the CTO of Xsensio, where he leads the development of the company’s proprietary Lab-on-Skin™ sensing platform. He holds a PhD in Chemistry, B.Sc in Materials Engineering and a B.A. in Physics. Before joining Xsensio, he spent several years developing novel biosensing concepts as an assistant professor at the University of Twente in the Netherlands and then moved to industry and worked as the CTO of the Dutch start up Biovolt BV, where he was managing the technology development of diagnostics assays for metabolic syndrome related health issues. Xsensio SA is a swiss start-up that develops innovative wearable systems that continuously monitor our physiological state to detect risks in real-time.
Esmeralda is the CEO of Xsensio, a company she co-founded a few years ago. Prior to Xsensio, she had several years of experience as manager at Boston-based investment firm Commons Capital where she was in charge of screening investment opportunities in a partnership with the Bill and Melinda Gates Foundation. She earned her MBA at the Massachusetts Institute of Technology (MIT), a B.S. and M.S. in Economics from ULB, Belgium and an executive degree in management from EPFL.
Adrian Heuss is a strategy consultant, conceptionalist and editor at advocacy. Initially, he wrote as a science journalist for various Swiss daily newspapers. After graduating from the Ringier School of Journalism, he worked for an international communications agency. He supported the feasability study of the microbiota vault.
As an Associate Professor of Epidemiology and Director of MD Anderson Cancer Center’s Bionutrition Research Core, my long-term goal is to refine and inform evidence-based dietary recommendations across the cancer continuum. Building on my training at Emory University, the American Cancer Society and the National Cancer Institute, my research at MD Anderson is increasingly motivated by the many unanswered questions and complexities surrounding nutrition, obesity, and the microbiome in our patients. Together with clinical and laboratory colleagues, we carefully collect data and “observe” habits, while pushing forward to more definitively answer these questions in dietary intervention trials.
Rob Knight is the founding Director of the Center for Microbiome Innovation and Professor of Pediatrics, Bioengineering, and Computer Science & Engineering at UC San Diego. He is a Fellow of the American Association for the Advancement of Science and received the 2017 Massry Prize. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including QIIME and UniFrac. His work has linked microbes to a range of health conditions, enhanced our understanding of microbes in many environments, and made high-throughput sequencing accessible to thousands of researchers around the world.
Kings College London
Dr. Nathan is consultant medical oncologist at Mount Vernon Cancer Centre, Northwood, UK. His specialist interests are the treatment of malignant melanoma and renal cell carcinoma. His clinical training was through Cambridge and London having had an earlier scientific career in academia and the pharmaceutical industry. He leads many academic and pharma sponsored clinical trials and has authored many high impact paper. He is a trustee of Melanoma Focus the UK national melanoma charity. He is EORTC Uveal Melanoma lead, International Rare Cancer Initiative (IRCI) UK Uveal melanoma lead and chairs the UK guideline group on Uveal Melanoma.
I am a medical oncologist at the department of Medical Oncology of the UMCG, the Netherlands. I studied biochemistry and medicine. I obtained my PhD degree in 1989 with the thesis ‘Mechanisms and circumvention of cellular resistance to cisplatin”. During my Dutch Cancer Society (KWF) fellowship I worked on gene therapy topics in several labs in the Netherlands, the UK (Chester Beatty Laboratories, London) and Belgium (Ludwig Institute, Brussels) and I was trained as a medical oncologist. At 1995 I started as a trained medical oncologist at the University Medical Center Groningen, the Netherlands. In 2011 I was appointed as a professor at the Department of Medical Oncology. My recent clinical research topics are to improve clinical outcome of patients with (locally) advanced melanoma, patients with locally advanced rectal cancer and to develop innovative molecular imaging techniques using whole body PET/CT on for example targets as PD-L1 and hormone receptors.
Yan (Janie) Jiang
Janie is a program/laboratory manager at MD Anderson Cancer Center. She received a PH.D. in nutritional biochemistry from Purdue University in West Lafayette Indiana. She did a postdoctoral training at University of Michigan in Ann Arbor Michigan. The research she is working on is around Dr. Jennifer McQuade’s “a control feeding study to investigate impact of dietary fiber on gut microbiome and immunity in melanoma patients”.
- Diet and Nutrition
Michal Rein is a registered dietitian, specializing in dietary interventions and modifications. Michal has a master in M.sc from the Ben-gurion university of the Negev and is currently a PhD student under the joint supervision of Prof Eran Segal from Weizmann institute ang Prof Shira Zelber-Sagi from the university of Haifa. As a researcher Michal is studying the effect of algorithm based personalized dietary recommendations tailored by the prediction of glycemic responses on the improvement of metabolic parameters and glycemic balance in various populations including healthy individuals, subjects with glucose intolerance and breast cancer survivors. Additionally, Michal is part of an ongoing developmental team studying the association between personal characteristics, food consumption and the emerging area of deep phenotyping and multi-omic data. Specifically on the influences of individual reaction to glucose and other health indicators. Personally, she chose to focus on nutrition thanks to the role it plays in health promotion and disease prevention and trying to invent tasty and easy recipes for her patients and family.
- Personalized dietary modification based on postprandial targeting diet
- Randomized clinical trial - design and monitoring
- Diabetes management
Thomas Vogl obtained a PhD in Molecular Biomedical Sciences in Austria. He was a visiting scientist at the Queensland University of Technology in Brisbane focusing on genomics. After working in the R&D department of Sandoz (Novartis) on biopharmaceutical production, he moved as a senior postdoc to the Weizmann Institute of Science (group of Prof. Eran Segal). Working on the interface between basic and applied research, Thomas is aiming to unravel interactions of the immune system with the microbiome. As a Seerave Fellow, Thomas is involved in profiling immune responses of cancer patients as well as developing novel COVID-19 diagnostics. Leveraging high throughput antibody repertoire profiling methodologies, they have created a novel high precision diagnostic for the detection of coronavirus (CoV) antibodies. This approach has for the first time revealed extensive cross-reactivity with animal CoVs, suggesting a novel diagnostic strategy for detecting future spillovers to humans.
- Microbiota-immune axis
- Machine learning
Roni has a practical electronics engineering from the national Handesaim school at the Technion, her final project was creating small gaming console from a processer screen and a mouse. Her bachelor is at biomedical engineering from the Technion, her final project was Vocal Vibes, were we used mechanical sensors as well as microphone and image analysis to assess vocal performances in basic speech therapy exercises, the project won first place at the entrepreneurs’ competition. Her current research is in Naama Geva-Zatorsky lab, studying the effect different nutrition and carbohydrate sources has on the microbiome functionality and how that mediate the changes nutrition has on the immune system.
Eran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, and analysis of heterogeneous high-throughput genomic data. His research focuses on Microbiome, Nutrition, Genetics, and their effect on health and disease. His aim is to develop personalized medicine based on big data from human cohorts.
Naama is combining systems-biology with microbiology and immunology to study the interactions between gut microbes and the host immune system in health and disease. She has characterized the host response to a variety of gut microbes and has applied a metabolic labeling approach to fluorescently label the anaerobic gut microbes. In addition, she is studying microbial genetic mechanisms that allow gut microbes to thrive the dynamic gut ecosystem and to co-op with bacteriophage. She is a recipient of the Alon Fellowship, the national and international UNESCO-L’Oreal award, the Human Frontiers fellowship, the EMBO fellowship, the John F. Kennedy Prize, the Teva Prize, and the Barenholz prize, for academic excellence. Naama received her B.Sc. from Tel Aviv University, double-majoring in Chemistry and Biology, with summa cum laude honors. Her M.Sc. and Ph.D., are from the Weizmann Institute, studying systems-biology of protein dynamics in cancer, with Prof. Uri Alon, completed with honors. Her postdoctoral training was at Harvard Medical School, studying gut microbiota-host interactions with Prof. Dennis Kasper.
Tal Gefen (PhD) is a lab manager and research associate at Naama Geva-Zatorsky’s lab “Microbiome – Host interaction”, Technion, Israel. Tal has graduated the Hebrew university of Jerusalem, where he conducted a research focusing on immunogenicity of therapeutic proteins. Later, as a postdoc under the guidance of Professor Eli Gilboa at University of Miami, he specialized in cancer immunotherapy and developed a novel molecule for the inhibition of checkpoint blockage via the TIM-3 receptor, expressed on exhausted T cells. At the Geva-Zatorsky’s lab, he is mainly focusing on microbial-immunological technology integration, development, and projects management.
Following a bachelors in Biochemistry and masters in Computational Biology, Thomas completed a PhD in Computational and Systems Biology at MIT. As a postdoc, also at MIT, he began studying the clinical impact of the gut microbiome with Prof. Eric Alm at the MIT Center for Microbiome Informatics and Therapeutics. It was during this time that he developed an interest in how we can use dietary interventions to shape the composition and metabolic output of the microbiome for therapeutic purposes. This led him to work on building a framework around personalised dietary fibre supplementation aiming to boost Short Chain Fatty Acid (SCFA) production in the gut. Thanks to the support of Seerave, Thomas has launched a clinical trial investigating the impact of different diets on plasma SCFAs and circulating markers of inflammation.
- Diet and the gut microbiome
- Short Chain Fatty Acids
- Machine learning
Noa is a PhD student in Namma Geva-Zatorsky’s lab, at the faculty of medicine, Technion, Israel. She received her BSc in Biochemical Engineering from the Chemical Engineering faculty at the Technion. She then started her Master’s degree in the Geva-Zatorsky lab and transitioned to the direct PhD tract. Her research project aims to reveal the environmental effects on the immunomodulatory functionality of gut bacteria . Her study combines microbiology and immunology using in vitro high throughput methods and Germ Free mice models. In the Seerave project she studies the mechanistic link between diet, gut bacterial immunomodulatory functionality and cancer. She does so by defining the effects of different carbon sources on bacterial immunomodulatory functionality in vitro, as well as the effects of diets on gut bacteria immunomodulatory functionality in gnotobiotic mice cancer models.
- Gut immunology
- GF mice models
- Bacterial metabolites
Marcel Salathé is a digital epidemiologist working at the interface of health and computer science. An associate Professor at EPFL where he heads the Digital Epidemiology Lab, Marcel works at the forefront of artificial intelligence and its application in health and other domains. His lab spun off AIcrowd, an AI challenge platform whose goal is to accelerate research on AI across multiple domains, and which is used by organizations such as OpenAI, Microsoft, Google, Amazon, Stanford University, and many others. Marcel is the founder of the MyFoodRepo platform, an AI-assisted tool to revolutionize food tracking in research cohorts.
Tessa is the Sr. Clincal Studies Coordinator in the Department of Melanoma and the McQuade Lab at MD Anderson Cancer Center. She received a MPH in Public Health, Epidemiology from the University of North Texas Health Science Center. She is currently working on Dr. Jennifer McQuade’s phase II clincal trial, “Diet and Immune Effects Trial: DIET – A randomized double blinded dietary intervention study in patients with metastatic melanom receiving immunotherapy“. Her main role is the recruitment and enrollment of patients to the phase II clinical trial and is the primary patient contact from the time of enrollment throughout their participation in the study.
- The DIET Study
- Melanoma Clinical Trials
- Melanoma diet studies
Talia Elena Salzmann
Dr. Jennifer Wargo is a professor, Department of Genomic Medicine, Division of Cancer Medicine, and professor, Department of Surgical Oncology, Division of Surgery, at The University of Texas MD Anderson Cancer Center. With a joint appointment in Surgical Oncology and Genomic Medicine, Professor Wargo leads critical research to better understand responses to therapy and to develop novel strategies to combat resistance. This includes her groundbreaking recent work elucidating the role of the gut microbiome in shaping responses to immunotherapy in patients with melanoma—with a manuscript describing this work published in Science and a clinical trial underway exploring optimal methods to manipulate the gut microbiome to enhance responses to cancer therapy. She is recognized internationally as a leader in cancer research and is leading innovative efforts globally.
Dr. McDonald is the Scientific Director for The Microsetta Initiative and the American Gut Project, run by the School of Medicine at UC San Diego. His research focuses on the complex microbial communities associated with humans, with the environment, and how to scale microbiome analysis to large sample sizes. He has played central roles in the development of highly cited analysis tools, such as QIIME, Qiita, and PICRUSt, a Genomic Standards Consortium file format called BIOM, and Greengenes, one of the main microbial taxonomies used in the field. Dr. McDonald received a BS and PhD in Computer Science from the University of Colorado at Boulder.
Jennifer Leigh McQuade
Dr. McQuade is a melanoma medical oncologist and physician-scientist at MD Anderson hosting a translational research program focused on understanding the interaction between host-level factors, tumor biology, immunity and outcomes. She is published in 41 peer-reviewed original research articles and authored or co-authored on 3 dozen other articles, abstracts and editorials. She has presented at conferences across the nation and has been featured in articles from both The New York Times and The Houston Chronicle for her paper in The Lancet Oncology titled Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Ashley E. Holly
Dr. Holly received her PhD from Cleveland State University with her doctoral research completed at the Cleveland Clinic. Her robust training in protein biology coupled with a strong interest in nutritional biochemistry led her to serve as a Research Scientist in the McQuade Lab at MD Anderson, where she was part of a team that performs controlled feeding studies. Her thirst for knowledge led Dr. Holly to earn an MBA degree giving her a unique skill set in the field! Currently, Dr. Holly is a Fellow in the Sharifi Lab at the Cleveland Clinic investigating diet, metabolism, and Prostate Cancer.
Sandrine Miller-Montgomery, Pharm.D., Ph.D. is the Co-Founder, President and CEO of Micronoma, the first cancer-detection company using liquid biopsy technology to detect and predict cancer at an early stage of the disease by analyzing the microbial signal with clinical-grade accuracy. Prior to this, she was executive director of UC San Diego’s Center for Microbiome Innovation that she co-led with Dr. Rob Knight. Before her time in academia, she had worked in large biotech and multinational companies as well as start-ups where she excelled at preparing companies for successful exits as shown by her work at Helixis, acquired by Illumina, and MO BIO Labs acquired by QIAGEN.
Unisversity of Trento
Andrew obtained his bachelor’s in Biology from Mackenzie University and was an intern at the Institute of Psychiatry investigating genetic polymorphisms associated with Alzheimer’s and Parkinson’s disease. For his Master’s in Oncology dissertation, obtained from AC Camargo Cancer Centre, he investigated the effects of alcohol and tobacco consumption on the oral microbiota. He obtained his PhD in Bioinformatics from the University of Sao Paulo. During his academic training, he has worked on several projects that included: "Studies of microbial diversity in the Zoological Park of the State of São Paulo (University of Sao Paulo)”, "Effects of short-chain fatty acids produced by probiotic bacteria in the prophylaxis and treatment of allergic airway inflammation” (Federal University of Sao Paulo) and “Identifying reproducible gut microbial signatures to detect colorectal cancer” (University of Trento). Currently, he is part of the Horizon 2020 funded project ”Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response”, where he supports project partners with computational analyses of gut microbiomes from several different cancer types. His current role in Seerave is to help in the analysis of the gut microbiome and response to immunotherapy in the PRIMM cohorts (King’s College London, University of Groningen and University of Trento).
Kevin the co-founder of Biomsense and is a skilled STEM commercialization leader with more than eight years’ experience in the healthcare space. Prior to joining BiomeSense, Kevin provided strategic and operational leadership as the Director of Operations for a seed-stage pharmacogenomics spinoff from the University of Chicago.
University of Trento
Nicola Segata, Ph.D., is Professor and Principal Investigator in the CIBIO Department at the University of Trento (Italy) and Principal Investigator at the European Institute of Oncology in Milan (Italy). His lab (http://segatalab.cibio.unitn.it/) employs experimental metagenomic tools and novel computational approaches to study the diversity of the microbiome across conditions and populations and its role in human diseases. The projects in the lab bring together computer scientists, microbiologists, statisticians, and clinicians and are generally focused on profiling microbiomes with strain-level resolution and on the meta-analysis of very large sets of metagenomes with novel computational tools.
Dr Bataille has been practising dermatology since 1989 in many teaching hospitals in London. She completed her PhD in 1995 at the CRUK/Royal London Hospital, London. In 2004, Dr Bataille moved to the West Hertfordshire NHS Trust where she runs a melanoma genetic clinics and supports the oncologists at the Mount Vernon Cancer Centre. Dr Bataille has been involved in many research projects over the last 25 years looking at the genetics of melanoma, naevi, pigmentation, gut microbiome and COVID skin manifestations. She has published extensively over the last 30 years Her H index on Google Scholar is 54.
Maria Gloria Dominguez
Maria Gloria Dominguez-Bello is the Henry Rutgers Professor of Microbiome and Health at Rutgers University. Her lab studies the impacts of modern practices on microbiomes, and strategies for restoration. She is a Fellow of the Infectious Disease Society of America (IDSA), and of the American Academy of Microbiology, and is a cofounder of the Microbiota Vault, a global initiative to preserve the diversity of the microbes relevant to human health.
Tim Spector is a medically qualified Professor of Epidemiology and Director of the TwinsUK registry at King’s College London. His current work focuses on the microbiome and nutrition, and he is co-founder of the data science company ZOE Ltd which has commercialised a home kit for personalised nutrition . He also the lead researcher behind the world's biggest citizen science health project - the ZOE Covid study of over 4 million people for which he was awarded an OBE. Having published more than 900 research articles, he is ranked in the top 100 of the world’s most cited scientists by Google. He is the author of four popular science books, including "The Diet Myth” and the most recent "Spoon Fed" which is a Sunday Times bestseller. He makes regular appearances on social and mainstream media.
Martin Blaser serves as Henry Rutgers Chair of the Human Microbiome and Director, Center for Advanced Biotechnology and Medicine at Rutgers University. For 20 years, he has been investigating the relationship of the human microbiome with the epidemics of obesity, diabetes, and asthma. He was President, Infectious Diseases Society of America, elected to the National Academy of Medicine and American Academy for Arts and Sciences, and currently chairs the Presidential Advisory Council for Combatting Antibiotic-Resistant Bacteria (PACCARB). He wrote Missing Microbes, now translated into 20 languages.
Karla Lee received her medical degree from Trinity College Dublin in 2012 and commenced early medical training in Dublin. In 2016 she completed an MSc at the Royal College of Surgeons, Ireland and moved to London to pursue academic oncology training. She is training as a medical oncologist at The Royal Marsden Hospital in London and has taken time away from this training to pursue a PhD at King’s College London. She is in the final year of her PhD and is working on a thesis investigating the impact of the gut microbiome and a number of other „omics“ on immune checkpoint inhibition for advanced melanoma. Karla hopes to combine academic and clinical work in her future career.
Dominik Steiger is Chief Executive Officer at EvalueScience Ltd, a consulting company specialized in advice, research, and conceptualization in the fields of biomedicine, health, and digital health. His work focusses on idea development and project management at the interfaces of research, policy, and regulation. He is coauthor of the Microbiota Vault Feasibility Study. As Secretary of the Microbiota Vault, he coordinates the launch of the initiative.
Professor Jack A Gilbert is a Professor in Pediatrics, the Scripps Institution of Oceanography, and Director of the Microbiome Core at University of California San Diego. He uses molecular analysis to test fundamental hypotheses in microbial ecology. Dr. Gilbert cofounded the Earth Microbiome Project, the Microbiota Vault, helps coordinate the American Gut Project, and cofounded BiomeSense Inc to develop microbiome collection tools. He has authored more than 350 peer reviewed publications and book chapters on microbial ecology and is the founding Editor in Chief of mSystems journal.
University of Basel
Prof. Adrian Egli is the Head of Clinical Bacteriology and Mycology of the University Hospital Basel and a research group leader at the Department of Biomedicine at the University of Basel. His research focuses on host-pathogen interaction and he and his team aims to understand antibiotic resistance and virulence development in single bacterial species and bacterial communities. He has published more than 150 articles, including high-ranked journals such as Nature Medicine, Nature, Plos Pathogens, and many more. Prof. Egli coordinates large national incentives in Switzerland including the SPHN/PHRT funded Personalized Swiss Sepsis Study and the Swiss Pathogen Surveillance Platform. He is a member of the Microbiota Vault pilot team in Switzerland.
Johannes Björk is a computational ecologist specialising in microbiome analysis through the lens of ecological theory. He received his PhD from the Polytechnic University of Barcelona under the supervision of theoretical ecologist José M. Montoya. In his dissertation, Johannes studied the structure and dynamics of the complex sponge-microbe interaction networks. Thereafter, he did a postdoc working on the gut microbiome of wild baboons. In this project, Johannes applied time-series models to better understand the relative contribution of the external environment, social interactions and host demographics in shaping the gut microbiome over time. Johannes is currently a Seerave postdoc working in the group of Rinse Weersma at the University Medical Center Groningen where he applies his unique perspective to increase our understanding of the gut microbiome’s role in ICI treatment to advanced melanoma.
- Microbiome ecology
- Longitudinal analysis
- Multi-omic analysis
- System biology
University of Lausanne
Pascale Vonaesch, MSc, MPH, PhD is an Assistant Professor at the University of Lausanne and a Principal Investigator within the NCCR Microbiomes. She was trained as a Microbiologist at the ETH in Zürich and the Ecole Normale Supérieure in Paris and subsequently performed her PhD thesis at the Institut of Microbiology at the ETH in Zürich, Switzerland on host-pathogen interactions and a postdoctoral research stay at the Institut Pasteur, Paris, France, where she initiated and led the Afribiota project, a translational research project aimed at eludicating the pathophysiology underlying stunted child growth. She then joined the Swiss Tropical and Public Health Institute for two years as a senior postdoc/ junior group leader to continue her work on undernutrition before moving with her group to the University of Lausanne. Her lab focuses on fundamental and translational/clinical research on the human intestinal ecosystem and the contribution of the microbiota to health and disease. In her research, she is especially interested in the role of the intestinal microbiome in childhood malnutrition and in the development of microbiota-targeted interventions.
Laura Bolte is a dietician currently pursuing an MD and PhD at the University Medical Center Groningen (UMCG). In 2013 she graduated in Nutritional sciences in Germany, where she performed research on diet-mediated endocrine and metabolic changes in diabetes, obesity and malnutrition. In 2017 she started her medical training which she is currently completing at the European Medical School Oldenburg-Groningen. Since 2019 she pursues a PhD in the group of Prof. Rinse Weersma to further investigate the therapeutic potential of diet and its role for the human gut microbiota. Her current research as a Seerave fellow aims to identify dietary factors and microbial targets to improve responsiveness to immunotherapy in cancer patients.
- diet-microbiome interaction
- intestinal inflammation
Christoph von Bieberstein
Christoph is co-founder and commercial director of HexagonFab. Before, Christoph was a senior consultant for McKinsey & Company working with a particular focus in market access for new therapeutics and vaccines in developed and emerging markets. Christoph holds a Master’s degree in Strategy and International Management from the University of St.Gallen. During his studies Christoph co-founded the non-profit organisation Liter of Light in Switzerland, the grass-roots solar-bottle movement to bring light to underprivileged communities around the world. Seerave has placed a seed investment into Hexagon Fab. Further, Hxagon Fab is a consortium member of the DIP project.
Ruizhi Wang is the Founder of HexagonFab is a start-up company based in Cambridge UK, The mission of HexagonFab is to create instruments that enable scientists to understand how proteins behave and what their properties are, faster, more accurately and more easily than ever before. During his PhD in Engineering at the University of Cambridge, Ruizhi worked on the scalable production of nanomaterials and processes to integrate these into devices such as sensors. The methods that he developed made it possible to create a new generation of nanomaterial-based sensors at industrially relevant scale.
University of Toronto
Shana is a world-renowned developer of technologies for diagnostics and therapeutic development. She is the co-founder of four life sciences startups including Arma Biosciences. Her > 250 scholarly publications have been cited > 25,000 time.
Niklaus Schneeberger leads the business unit Active Implants & Microsystems at Helbling Technik Bern. Helbling Technik supports their clients in the engineering development of innovative products and technologies. Niklaus has earned a PhD in Physics at ETH Zurich developing infrared microsensors in CMOS technology and an MBA in management of technology from EPFL Lausanne. He has over 25 years of experience in technology and product development in the area of highly miniaturized sensors, medical devices and microsystem technology.
Marion Badi works as project engineer in the Active Implants & Microsystems unit at Helbling Technik Bern. Helbling Technik supports their clients in the engineering development of innovative products and technologies. Marion earned a PhD in electrical engineering at EPFL working on the development of implantable electrical therapies targeting neurological injuries. She has expertise in diverse engineering areas such as electronics, modeling, and signal processing with a focus on biomedical applications.
John de La Parra
Periodic Table of Food
Dr. John de la Parra is an ethnobotanist and plant chemist with expertise in food crops and medicinal plants. He is currently the President of the Society for Economic Botany. John is also Manager of the Global Food Portfolio at The Rockefeller Foundation where his work focuses on the management of the Periodic Table of Food Initiative, a global effort to create a public database of the biochemical composition and function of the food we eat using the latest mass spectrometry technologies and bioinformatics. He also holds appointments as an Associate at Harvard University and a Lecturer at Tufts University where his expertise encompasses ethnobotany, food system innovation, agriculture, and medicinal plants. He has held additional appointments as a Research Scientist at MIT and a Lecturer of Biotechnology at Northeastern University.
Léa Montégut is a Ph.D. candidate in Pr. Guido Kroemer’s laboratory “Metabolism, cancer and Immunity”. She studied basic mathematics, physics and chemistry before she specialized in biology during her M. Sc. at École Polytechnique (France). She did her Master’s thesis at Columbia University (New York) in Pr. Gerard Ateshian’s Musculoskeletal Biomechanics Laboratory, working on 3D culture of cartilage implants. She then spent two years studying metabolic therapy for optimization of antibody production in Pr. Mario Jolicoeur’s laboratory of applied metabolomics in Polytechnique Montréal. She is now focusing on the role of ACBP, a metabolic factor which increases appetite and shifts lipids metabolism towards fat storage, in cancer development and treatment.
- Appetite regulation
- Metabolism modelling
- Imaging flow cytometry
- Breast cancer models
Isabelle MARTINS received her Ph.D. from the University of Paris, France, in 2008. Her thesis focused on the pathological expression of MHC II molecules in melanomas. After her PhD, she joined the Gustave Roussy Institute as a post-doctoral fellow where she started studying the cellular and molecular mechanisms involved in the immunogenicity of cell death after chemotherapy (2008-2013). In 2017, she completed her post-doctoral training investigating the cell death processes involved in the elimination of cancer cells following exposure to ionizing radiation. She is currently a Senior Scientist in the laboratory “Metabolism, Cancer and Immunity” of Pr. Guido Kroemer, where she investigates several aspects of cell death, metabolism and cancer developing technological innovations.
- Cell death
- Metabolism obesity
- Anti-tumour immunity
Marine Fidelle is a PharmD level passionate about immunology. During her PhD (2018-2021) in Pr. Zitvogel’s lab, she managed to elucidate the vicious immunosuppressive mechanism of antibiotic treatments in patients receiving immunotherapy with immune checkpoint inhibitors (ICIs). She wants to explore therapeutic interventions to circumvent the deleterious impact of gut dysbiosis in patients with cancer. In the meantime, she has discovered a promising biomarker of ICIs response and prognosis. She is also implicated in a multicentric lung cancer screening programme.
- Diet and Metabolism
- Gut microbiome involvement in cancer
- MultiOmics Analysis
Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris, Director of the research team "Metabolism, Cancer and Immunity" of the French Medical Research Council, Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. Dr. Kroemer’s work focuses on the pathophysiological implications of cell stress and death in the context of aging, cancer and inflammation. He discovered the the cytoprotective and antiaging effects of macroautophagy, as well as the decisive role of immunogenic cell death in anticancer treatments.
Prof. L. Zitvogel, MD (Clinical Oncology), PhD (Tumor Immunology), full professor at the University Paris Saclay, graduated in Medical Oncology in 1992. Scientific career first at the University of Pittsburgh, US. Became Research Director at Institut National de la Santé et Recherche Médicale U1015, and Scientific Director of the Clinicobiome program at Gustave Roussy, the largest cancer Center in Europe in 1998. Actively contributed to the field of cancer immunology and immunotherapy. Pionner of the concepts of immunogenic cell death and gut microbiota in cancer immunosurveillance and therapies. Recipient of many awards: French National Academy of Medicine, Translation Research INSERM Prize, the ASCO-SITC, Brupbacher Awards 2017, ESMO Immuno-Oncology Award 2017, Baillet Latour Prize 2019 and the Griffuel Prize 2019.
Dr. Jonathan Pol is a permanent researcher at INSERM in Pr. Guido Kroemer’s team (Centre de Recherche des Cordeliers | Institut Gustave Roussy, France), where he leads a group in Immuno-Oncology. He obtained his PhD in Molecular and Medical Virology in 2008 (Paris, France). Then, he joined the teams of Drs. Brian Lichty and Yonghong Wan for 5 years at McMaster University (ON, Canada) to develop oncolytic cancer vaccines. In 2014, he returned to France in Pr. Kroemer’s laboratory to study cancer immunogenic cell death and immunosurveillance, and pursue the development of cancer immunotherapies. In particular, his work has demonstrated that caloric restriction mimetics stimulate cancer immunosurveillance and improve the efficacy of chemo-immunotherapy.
Alumni at Laurence Zitvogel Lab
Gladys FERRERE is a researcher and she studies the impact of microbiota and diet in different pathologies. In 2015, she obtained her pHD on the role of microbiota in liver disease. After she joined Zitvogel’s team at Gustave Roussy Institute. She showed the impact of ketogenic diet and the metabolites associated on the immunotherapies responses in preclinical models. In Clinicobiome program, a clinical trial named KETOREIN is open since november 2021 and tests the diet she found. She worksnow at the national Institute in food research and tries to find pro- or prebiotic that can improve people’s life.
- Tumor immunology
Santorio is committed to ensuring that your privacy is protected. That’s why we have taken the necessary steps to meet worldwide data privacy requirements, according to the EU General Data Protection Regulation and the laws of Switzerland, which regulate the storage, process, access, and transfer of personal data.
Should we ask you to provide certain information by which you can be identified when using this Website, we will only collect it if you choose to give it to us. We do not share any of your personally identifiable information with third parties for their own marketing use unless you explicitly give us permission to do so. You can be assured that the collected personal information will only be used in accordance with this privacy statement.
Please review this privacy statement if you wish to know more about how we collect, use, share, and protect information online.
What we collect
We may collect the following types of information:
Personal identifiable information: You can visit our Website without providing any personal information.
We may collect it only when you choose to submit it to us.
We may also collect other information about you that you provide by responding to our questions or surveys.
For Human Resources purposes only: Personal documents such as copies of an identity card, medical insurance card, Curriculum Vitae, etc.
Aggregate information: We sometimes gather anonymous data to produce aggregated statistical information, such as the number of visitors to the Website, origin of the traffic, etc. which we use to improve our products and services.
Automatically collected information: Automatic technologies and services we use may include, for example, collection of web server logs/IP addresses, cookies (read more on this below), etc. These tracking technologies do not automatically obtain personally identifiable information about you.
What Are Cookies
For more general information on cookies see the Wikipedia article on HTTP Cookies.
You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the site. Therefore it is recommended that you do not disable cookies.
The Cookies We Set
When you submit data through a form such as those found on contact pages or comment forms cookies may be set to remember your user details for future correspondence.
In order to provide you with a great experience on this site, we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences, we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.
Third Party Cookies
This site uses Google Analytics which is one of the most widespread and trusted analytics solutions on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.
For more information on Google Analytics cookies, see the official Google Analytics page.
Third-party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.
From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.
As we sell products it’s important for us to understand statistics about how many of the visitors to our site actually make a purchase and as such this is the kind of data that these cookies will track. This is important to you as it means that we can accurately make business predictions that allow us to monitor our advertising and product costs to ensure the best possible price.
In some cases, we may provide you with custom content based on what you tell us about yourself either directly or indirectly by linking a social media account. These types of cookies simply allow us to provide you with content that we feel may be of interest to you.
We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; LinkedIn, Twitter, Vimeo, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.
Hopefully, that has clarified things for you and as was previously mentioned if there is something that you aren’t sure whether you need or not it’s usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.
However, if you are still looking for more information then you can contact us through one of our preferred contact methods.